CRISPR Therapeutics AG's Total Assets for the quarter that ended in Dec. 2023 was $2,229.6 Mil.
Warning Sign:
If a company builds assets at 71% a year, faster than its revenue growth rate of 27.1% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, CRISPR Therapeutics AG's average Total Assets Growth Rate was 25.30% per year.
During the past 3 years, the average Total Assets Growth Rate was 57.30% per year.
During the past 5 years, the average Total Assets Growth Rate was 71.00% per year.
During the past 10 years, CRISPR Therapeutics AG's highest 3-Year average Total Assets Growth Rate was 278.60%. The lowest was 51.50%. And the median was 63.30%.
Total Assets is connected with ROA %. CRISPR Therapeutics AG's annualizedROA % for the quarter that ended in Dec. 2023 was 16.56%. Total Assets is also linked to Revenue through Asset Turnover. CRISPR Therapeutics AG's Asset Turnover for the quarter that ended in Dec. 2023 was 0.09.
CRISPR Therapeutics AG Total Assets Historical Data
The historical data trend for CRISPR Therapeutics AG's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
CRISPR Therapeutics AG Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Total Assets
1,066.75
1,827.97
2,751.88
2,243.06
2,229.57
CRISPR Therapeutics AG Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Total Assets
2,243.06
2,244.36
2,197.01
2,086.83
2,229.57
CRISPR Therapeutics AG Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
CRISPR Therapeutics AG's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRISPR Therapeutics AG (NAS:CRSP) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
CRISPR Therapeutics AG's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
CRISPR Therapeutics AG Total Assets Related Terms
Thank you for viewing the detailed overview of CRISPR Therapeutics AG's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
CRISPR Therapeutics AG (CRISPR Therapeutics AG) Business Description
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRSP has been successfully added to your 